context stringlengths 21 33.9k | category stringclasses 2 values | entity stringlengths 1 12 | entity_type stringclasses 5 values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
The 2023 Convertible Notes were initially accounted for in accordance with authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. The guidance required the carrying amount of the liability component to be estimated by estimating the fair value of a similar liability that does not have an associated conversion feature. Because at issuance we had no outstanding non-convertible public debt, we determined that market-traded senior, unsecured corporate bonds represented a similar liability without a conversion option. Based on market data available for publicly traded, senior, unsecured corporate bonds issued by companies in our industry, and with similar maturities to the 2023 Convertible Notes, we estimated an implied interest rate of 3.7 %, assuming no conversion option. The estimated implied interest rate was applied to the 2023 Convertible Notes, which resulted in a fair value of the liability component in aggregate of $ 624 million upon issuance, calculated as the present value of implied future payments based on the $ 750 million aggregate principal amount. The $ 126 million difference ($ 93 million, net of tax) between the aggregate principal amount of $ 750 million and the estimated fair value of the liability component was recorded in additional paid-in capital as the 2023 Convertible Notes were not considered redeemable. As of January 3, 2022, we adopted ASU 2020-06, which removed the requirement to separate the embedded conversion feature from the notes and requires the notes to be accounted for as a single liability measured at amortized cost. Accordingly, we reclassified the unamortized debt discount from additional paid-in capital to convertible senior notes in the consolidated balance sheets on January 3, 2022. This resulted in an increase to retained earnings and a decrease to additional paid-in capital of $ 61 million and $ 93 million, respectively. | text | 61 | monetaryItemType | text: <entity> 61 </entity> <entity type> monetaryItemType </entity type> <context> The 2023 Convertible Notes were initially accounted for in accordance with authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. The guidance required the carrying amount of the liability component to be estimated by estimating the fair value of a similar liability that does not have an associated conversion feature. Because at issuance we had no outstanding non-convertible public debt, we determined that market-traded senior, unsecured corporate bonds represented a similar liability without a conversion option. Based on market data available for publicly traded, senior, unsecured corporate bonds issued by companies in our industry, and with similar maturities to the 2023 Convertible Notes, we estimated an implied interest rate of 3.7 %, assuming no conversion option. The estimated implied interest rate was applied to the 2023 Convertible Notes, which resulted in a fair value of the liability component in aggregate of $ 624 million upon issuance, calculated as the present value of implied future payments based on the $ 750 million aggregate principal amount. The $ 126 million difference ($ 93 million, net of tax) between the aggregate principal amount of $ 750 million and the estimated fair value of the liability component was recorded in additional paid-in capital as the 2023 Convertible Notes were not considered redeemable. As of January 3, 2022, we adopted ASU 2020-06, which removed the requirement to separate the embedded conversion feature from the notes and requires the notes to be accounted for as a single liability measured at amortized cost. Accordingly, we reclassified the unamortized debt discount from additional paid-in capital to convertible senior notes in the consolidated balance sheets on January 3, 2022. This resulted in an increase to retained earnings and a decrease to additional paid-in capital of $ 61 million and $ 93 million, respectively. </context> | us-gaap:RetainedEarningsAccumulatedDeficit |
On January 4, 2023, we entered into a new credit agreement (the Revolving Credit Agreement), which provides us with a $ 750 million senior unsecured five-year revolving credit facility, including a $ 40 million sublimit for swingline borrowings and a $ 50 million sublimit for letters of credit (the Revolving Credit Facility). Proceeds of the loans under the Revolving Credit Facility may be used to finance working capital needs and for general corporate purposes. The credit agreement dated as of March 8, 2021 and the commitments thereunder were terminated as of January 4, 2023. | text | 750 | monetaryItemType | text: <entity> 750 </entity> <entity type> monetaryItemType </entity type> <context> On January 4, 2023, we entered into a new credit agreement (the Revolving Credit Agreement), which provides us with a $ 750 million senior unsecured five-year revolving credit facility, including a $ 40 million sublimit for swingline borrowings and a $ 50 million sublimit for letters of credit (the Revolving Credit Facility). Proceeds of the loans under the Revolving Credit Facility may be used to finance working capital needs and for general corporate purposes. The credit agreement dated as of March 8, 2021 and the commitments thereunder were terminated as of January 4, 2023. </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
On January 4, 2023, we entered into a new credit agreement (the Revolving Credit Agreement), which provides us with a $ 750 million senior unsecured five-year revolving credit facility, including a $ 40 million sublimit for swingline borrowings and a $ 50 million sublimit for letters of credit (the Revolving Credit Facility). Proceeds of the loans under the Revolving Credit Facility may be used to finance working capital needs and for general corporate purposes. The credit agreement dated as of March 8, 2021 and the commitments thereunder were terminated as of January 4, 2023. | text | 40 | monetaryItemType | text: <entity> 40 </entity> <entity type> monetaryItemType </entity type> <context> On January 4, 2023, we entered into a new credit agreement (the Revolving Credit Agreement), which provides us with a $ 750 million senior unsecured five-year revolving credit facility, including a $ 40 million sublimit for swingline borrowings and a $ 50 million sublimit for letters of credit (the Revolving Credit Facility). Proceeds of the loans under the Revolving Credit Facility may be used to finance working capital needs and for general corporate purposes. The credit agreement dated as of March 8, 2021 and the commitments thereunder were terminated as of January 4, 2023. </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
On January 4, 2023, we entered into a new credit agreement (the Revolving Credit Agreement), which provides us with a $ 750 million senior unsecured five-year revolving credit facility, including a $ 40 million sublimit for swingline borrowings and a $ 50 million sublimit for letters of credit (the Revolving Credit Facility). Proceeds of the loans under the Revolving Credit Facility may be used to finance working capital needs and for general corporate purposes. The credit agreement dated as of March 8, 2021 and the commitments thereunder were terminated as of January 4, 2023. | text | 50 | monetaryItemType | text: <entity> 50 </entity> <entity type> monetaryItemType </entity type> <context> On January 4, 2023, we entered into a new credit agreement (the Revolving Credit Agreement), which provides us with a $ 750 million senior unsecured five-year revolving credit facility, including a $ 40 million sublimit for swingline borrowings and a $ 50 million sublimit for letters of credit (the Revolving Credit Facility). Proceeds of the loans under the Revolving Credit Facility may be used to finance working capital needs and for general corporate purposes. The credit agreement dated as of March 8, 2021 and the commitments thereunder were terminated as of January 4, 2023. </context> | us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity |
Loans under the Revolving Credit Facility will have a variable interest rate based on either the term secured overnight financing rate (SOFR) or the alternate base rate, plus an applicable rate that varies with our debt rating and, in the case of loans bearing interest based on term SOFR, a credit spread adjustment equal to 0.10 % per annum. The Revolving Credit Agreement includes an option for us to elect to increase commitments under the credit facility or enter into one or more tranches of term loans in the aggregate principal amount of up to $ 250 million, subject to consent of the lenders providing the additional commitments or loans and certain other conditions. | text | 0.10 | percentItemType | text: <entity> 0.10 </entity> <entity type> percentItemType </entity type> <context> Loans under the Revolving Credit Facility will have a variable interest rate based on either the term secured overnight financing rate (SOFR) or the alternate base rate, plus an applicable rate that varies with our debt rating and, in the case of loans bearing interest based on term SOFR, a credit spread adjustment equal to 0.10 % per annum. The Revolving Credit Agreement includes an option for us to elect to increase commitments under the credit facility or enter into one or more tranches of term loans in the aggregate principal amount of up to $ 250 million, subject to consent of the lenders providing the additional commitments or loans and certain other conditions. </context> | us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 |
In the normal course of business, we enter into agreements to purchase goods or services that are not cancelable without penalty, primarily related to licensing and supply arrangements. For those agreements with variable terms, we do not estimate the total obligation beyond any minimum quantities or pricing as of the reporting date. Licensing agreements under which we commit to minimum royalty payments, some of which are subject to adjustment, may be terminated prior to the expiration of underlying intellectual property under certain circumstances. Annual minimum payments for noncancelable purchase obligations as of December 29, 2024 totaled $ 212 million, approximately half of which are due within the next twelve months. | text | 212 | monetaryItemType | text: <entity> 212 </entity> <entity type> monetaryItemType </entity type> <context> In the normal course of business, we enter into agreements to purchase goods or services that are not cancelable without penalty, primarily related to licensing and supply arrangements. For those agreements with variable terms, we do not estimate the total obligation beyond any minimum quantities or pricing as of the reporting date. Licensing agreements under which we commit to minimum royalty payments, some of which are subject to adjustment, may be terminated prior to the expiration of underlying intellectual property under certain circumstances. Annual minimum payments for noncancelable purchase obligations as of December 29, 2024 totaled $ 212 million, approximately half of which are due within the next twelve months. </context> | us-gaap:PurchaseObligation |
The 2015 Stock and Incentive Compensation Plan (the 2015 Stock Plan) and the New Hire Stock and Incentive Plan allow for the issuance of stock options, performance stock options, restricted stock units and awards and performance stock units. In 2023, the Company’s stockholders approved an amended and restated version of the 2015 Stock Plan and increased the maximum number of shares authorized for issuance by 8.0 million shares. In connection with the GRAIL Spin-Off, all unvested RSU and PSU were equitably adjusted pursuant to the plan to preserve their intrinsic value and the number of shares reserved for issuance under the 2015 Stock Plan was increased by 160,000 shares. As of December 29, 2024, approximately 5.4 million shares remained available for future grants under the 2015 Stock Plan. There is no set number of shares reserved for issuance under the New Hire Stock and Incentive Plan. | text | 8.0 | sharesItemType | text: <entity> 8.0 </entity> <entity type> sharesItemType </entity type> <context> The 2015 Stock and Incentive Compensation Plan (the 2015 Stock Plan) and the New Hire Stock and Incentive Plan allow for the issuance of stock options, performance stock options, restricted stock units and awards and performance stock units. In 2023, the Company’s stockholders approved an amended and restated version of the 2015 Stock Plan and increased the maximum number of shares authorized for issuance by 8.0 million shares. In connection with the GRAIL Spin-Off, all unvested RSU and PSU were equitably adjusted pursuant to the plan to preserve their intrinsic value and the number of shares reserved for issuance under the 2015 Stock Plan was increased by 160,000 shares. As of December 29, 2024, approximately 5.4 million shares remained available for future grants under the 2015 Stock Plan. There is no set number of shares reserved for issuance under the New Hire Stock and Incentive Plan. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized |
The 2015 Stock and Incentive Compensation Plan (the 2015 Stock Plan) and the New Hire Stock and Incentive Plan allow for the issuance of stock options, performance stock options, restricted stock units and awards and performance stock units. In 2023, the Company’s stockholders approved an amended and restated version of the 2015 Stock Plan and increased the maximum number of shares authorized for issuance by 8.0 million shares. In connection with the GRAIL Spin-Off, all unvested RSU and PSU were equitably adjusted pursuant to the plan to preserve their intrinsic value and the number of shares reserved for issuance under the 2015 Stock Plan was increased by 160,000 shares. As of December 29, 2024, approximately 5.4 million shares remained available for future grants under the 2015 Stock Plan. There is no set number of shares reserved for issuance under the New Hire Stock and Incentive Plan. | text | 5.4 | sharesItemType | text: <entity> 5.4 </entity> <entity type> sharesItemType </entity type> <context> The 2015 Stock and Incentive Compensation Plan (the 2015 Stock Plan) and the New Hire Stock and Incentive Plan allow for the issuance of stock options, performance stock options, restricted stock units and awards and performance stock units. In 2023, the Company’s stockholders approved an amended and restated version of the 2015 Stock Plan and increased the maximum number of shares authorized for issuance by 8.0 million shares. In connection with the GRAIL Spin-Off, all unvested RSU and PSU were equitably adjusted pursuant to the plan to preserve their intrinsic value and the number of shares reserved for issuance under the 2015 Stock Plan was increased by 160,000 shares. As of December 29, 2024, approximately 5.4 million shares remained available for future grants under the 2015 Stock Plan. There is no set number of shares reserved for issuance under the New Hire Stock and Incentive Plan. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
In Q1 2023, we granted RSU that were to be settled in cash if stockholder approval to increase our share reserve under the amended and restated 2015 Stock Plan was not obtained. In Q2 2023, the Company’s stockholders approved an amended and restated version of the 2015 Stock Plan and increased the maximum number of shares authorized for issuance. Upon such approval, all RSU previously accounted for as liability-classified awards, approximately 557,000 RSU, were reclassified to stockholders equity and accounted for prospectively as equity awards. There were no RSU liability-classified awards outstanding as of December 29, 2024 or December 31, 2023. | text | 557000 | sharesItemType | text: <entity> 557000 </entity> <entity type> sharesItemType </entity type> <context> In Q1 2023, we granted RSU that were to be settled in cash if stockholder approval to increase our share reserve under the amended and restated 2015 Stock Plan was not obtained. In Q2 2023, the Company’s stockholders approved an amended and restated version of the 2015 Stock Plan and increased the maximum number of shares authorized for issuance. Upon such approval, all RSU previously accounted for as liability-classified awards, approximately 557,000 RSU, were reclassified to stockholders equity and accounted for prospectively as equity awards. There were no RSU liability-classified awards outstanding as of December 29, 2024 or December 31, 2023. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber |
We recognized share-based compensation expense on these cash-based equity incentive awards of $ 52 million in 2024, prior to the Spin-Off, and $ 95 million and $ 67 million in 2023 and 2022, respectively. | text | 52 | monetaryItemType | text: <entity> 52 </entity> <entity type> monetaryItemType </entity type> <context> We recognized share-based compensation expense on these cash-based equity incentive awards of $ 52 million in 2024, prior to the Spin-Off, and $ 95 million and $ 67 million in 2023 and 2022, respectively. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
We recognized share-based compensation expense on these cash-based equity incentive awards of $ 52 million in 2024, prior to the Spin-Off, and $ 95 million and $ 67 million in 2023 and 2022, respectively. | text | 95 | monetaryItemType | text: <entity> 95 </entity> <entity type> monetaryItemType </entity type> <context> We recognized share-based compensation expense on these cash-based equity incentive awards of $ 52 million in 2024, prior to the Spin-Off, and $ 95 million and $ 67 million in 2023 and 2022, respectively. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
We recognized share-based compensation expense on these cash-based equity incentive awards of $ 52 million in 2024, prior to the Spin-Off, and $ 95 million and $ 67 million in 2023 and 2022, respectively. | text | 67 | monetaryItemType | text: <entity> 67 </entity> <entity type> monetaryItemType </entity type> <context> We recognized share-based compensation expense on these cash-based equity incentive awards of $ 52 million in 2024, prior to the Spin-Off, and $ 95 million and $ 67 million in 2023 and 2022, respectively. </context> | us-gaap:AllocatedShareBasedCompensationExpense |
In connection with the acquisition of GRAIL, we assumed a performance-based award for which vesting was based on GRAIL’s future revenues and had an aggregate potential value of up to $ 78 million. Prior to the Spin-Off of GRAIL, it was not probable that the performance conditions associated with the award would be achieved and, therefore, no share-based compensation expense was recognized in the consolidated statements of operations. In connection with the Spin-Off, this award was assumed by GRAIL. For a period of 2.5 years following the Spin-Off, we are obligated to indemnify GRAIL for cash payments that become earned and payable related to this award. The indemnification is accounted for in accordance with ASC 460. As of December 29, 2024, we recognized a non-contingent liability of $ 1 million for this indemnification, with a corresponding charge to additional paid-in capital. | text | 1 | monetaryItemType | text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the acquisition of GRAIL, we assumed a performance-based award for which vesting was based on GRAIL’s future revenues and had an aggregate potential value of up to $ 78 million. Prior to the Spin-Off of GRAIL, it was not probable that the performance conditions associated with the award would be achieved and, therefore, no share-based compensation expense was recognized in the consolidated statements of operations. In connection with the Spin-Off, this award was assumed by GRAIL. For a period of 2.5 years following the Spin-Off, we are obligated to indemnify GRAIL for cash payments that become earned and payable related to this award. The indemnification is accounted for in accordance with ASC 460. As of December 29, 2024, we recognized a non-contingent liability of $ 1 million for this indemnification, with a corresponding charge to additional paid-in capital. </context> | us-gaap:DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining |
The 2000 Employee Stock Purchase Plan, or ESPP, permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. The price at which stock is purchased under the ESPP is equal to 85 % of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. The initial offering period commenced in July 2000. During 2024, 2023, and 2022, approximately 0.5 million, 0.4 million, and 0.3 million shares, respectively, were issued under the ESPP. As of December 29, 2024, approximately 12.4 million shares remained available for issuance under the ESPP, which includes an increase of 0.5 million shares pursuant to the terms of the ESPP to account for the GRAIL Spin-Off. | text | 85 | percentItemType | text: <entity> 85 </entity> <entity type> percentItemType </entity type> <context> The 2000 Employee Stock Purchase Plan, or ESPP, permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. The price at which stock is purchased under the ESPP is equal to 85 % of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. The initial offering period commenced in July 2000. During 2024, 2023, and 2022, approximately 0.5 million, 0.4 million, and 0.3 million shares, respectively, were issued under the ESPP. As of December 29, 2024, approximately 12.4 million shares remained available for issuance under the ESPP, which includes an increase of 0.5 million shares pursuant to the terms of the ESPP to account for the GRAIL Spin-Off. </context> | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent |
The 2000 Employee Stock Purchase Plan, or ESPP, permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. The price at which stock is purchased under the ESPP is equal to 85 % of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. The initial offering period commenced in July 2000. During 2024, 2023, and 2022, approximately 0.5 million, 0.4 million, and 0.3 million shares, respectively, were issued under the ESPP. As of December 29, 2024, approximately 12.4 million shares remained available for issuance under the ESPP, which includes an increase of 0.5 million shares pursuant to the terms of the ESPP to account for the GRAIL Spin-Off. | text | 0.5 | sharesItemType | text: <entity> 0.5 </entity> <entity type> sharesItemType </entity type> <context> The 2000 Employee Stock Purchase Plan, or ESPP, permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. The price at which stock is purchased under the ESPP is equal to 85 % of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. The initial offering period commenced in July 2000. During 2024, 2023, and 2022, approximately 0.5 million, 0.4 million, and 0.3 million shares, respectively, were issued under the ESPP. As of December 29, 2024, approximately 12.4 million shares remained available for issuance under the ESPP, which includes an increase of 0.5 million shares pursuant to the terms of the ESPP to account for the GRAIL Spin-Off. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod |
The 2000 Employee Stock Purchase Plan, or ESPP, permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. The price at which stock is purchased under the ESPP is equal to 85 % of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. The initial offering period commenced in July 2000. During 2024, 2023, and 2022, approximately 0.5 million, 0.4 million, and 0.3 million shares, respectively, were issued under the ESPP. As of December 29, 2024, approximately 12.4 million shares remained available for issuance under the ESPP, which includes an increase of 0.5 million shares pursuant to the terms of the ESPP to account for the GRAIL Spin-Off. | text | 0.4 | sharesItemType | text: <entity> 0.4 </entity> <entity type> sharesItemType </entity type> <context> The 2000 Employee Stock Purchase Plan, or ESPP, permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. The price at which stock is purchased under the ESPP is equal to 85 % of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. The initial offering period commenced in July 2000. During 2024, 2023, and 2022, approximately 0.5 million, 0.4 million, and 0.3 million shares, respectively, were issued under the ESPP. As of December 29, 2024, approximately 12.4 million shares remained available for issuance under the ESPP, which includes an increase of 0.5 million shares pursuant to the terms of the ESPP to account for the GRAIL Spin-Off. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod |
The 2000 Employee Stock Purchase Plan, or ESPP, permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. The price at which stock is purchased under the ESPP is equal to 85 % of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. The initial offering period commenced in July 2000. During 2024, 2023, and 2022, approximately 0.5 million, 0.4 million, and 0.3 million shares, respectively, were issued under the ESPP. As of December 29, 2024, approximately 12.4 million shares remained available for issuance under the ESPP, which includes an increase of 0.5 million shares pursuant to the terms of the ESPP to account for the GRAIL Spin-Off. | text | 0.3 | sharesItemType | text: <entity> 0.3 </entity> <entity type> sharesItemType </entity type> <context> The 2000 Employee Stock Purchase Plan, or ESPP, permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. The price at which stock is purchased under the ESPP is equal to 85 % of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. The initial offering period commenced in July 2000. During 2024, 2023, and 2022, approximately 0.5 million, 0.4 million, and 0.3 million shares, respectively, were issued under the ESPP. As of December 29, 2024, approximately 12.4 million shares remained available for issuance under the ESPP, which includes an increase of 0.5 million shares pursuant to the terms of the ESPP to account for the GRAIL Spin-Off. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod |
The 2000 Employee Stock Purchase Plan, or ESPP, permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. The price at which stock is purchased under the ESPP is equal to 85 % of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. The initial offering period commenced in July 2000. During 2024, 2023, and 2022, approximately 0.5 million, 0.4 million, and 0.3 million shares, respectively, were issued under the ESPP. As of December 29, 2024, approximately 12.4 million shares remained available for issuance under the ESPP, which includes an increase of 0.5 million shares pursuant to the terms of the ESPP to account for the GRAIL Spin-Off. | text | 12.4 | sharesItemType | text: <entity> 12.4 </entity> <entity type> sharesItemType </entity type> <context> The 2000 Employee Stock Purchase Plan, or ESPP, permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. The price at which stock is purchased under the ESPP is equal to 85 % of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. The initial offering period commenced in July 2000. During 2024, 2023, and 2022, approximately 0.5 million, 0.4 million, and 0.3 million shares, respectively, were issued under the ESPP. As of December 29, 2024, approximately 12.4 million shares remained available for issuance under the ESPP, which includes an increase of 0.5 million shares pursuant to the terms of the ESPP to account for the GRAIL Spin-Off. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
In August 2024, our Board of Directors authorized a new share repurchase program, which cancels and supersedes all prior and available repurchase authorizations, to repurchase up to $ 1.5 billion of our outstanding common stock. The repurchases may be completed through open market purchases, pursuant to Rule 10b5-1 or Rule 10b-18, or through an accelerated share repurchase program. Authorizations to repurchase up to $ 1.4 billion of our outstanding common stock remained available as of December 29, 2024. We did not repurchase any shares during 2023 or 2022. | text | 1.4 | monetaryItemType | text: <entity> 1.4 </entity> <entity type> monetaryItemType </entity type> <context> In August 2024, our Board of Directors authorized a new share repurchase program, which cancels and supersedes all prior and available repurchase authorizations, to repurchase up to $ 1.5 billion of our outstanding common stock. The repurchases may be completed through open market purchases, pursuant to Rule 10b5-1 or Rule 10b-18, or through an accelerated share repurchase program. Authorizations to repurchase up to $ 1.4 billion of our outstanding common stock remained available as of December 29, 2024. We did not repurchase any shares during 2023 or 2022. </context> | us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 |
Subsequent to December 29, 2024 and through February 11, 2025, we repurchased an additional 1.0 million shares of our common stock for $ 126 million. | text | 1.0 | sharesItemType | text: <entity> 1.0 </entity> <entity type> sharesItemType </entity type> <context> Subsequent to December 29, 2024 and through February 11, 2025, we repurchased an additional 1.0 million shares of our common stock for $ 126 million. </context> | us-gaap:TreasuryStockSharesAcquired |
Subsequent to December 29, 2024 and through February 11, 2025, we repurchased an additional 1.0 million shares of our common stock for $ 126 million. | text | 126 | monetaryItemType | text: <entity> 126 </entity> <entity type> monetaryItemType </entity type> <context> Subsequent to December 29, 2024 and through February 11, 2025, we repurchased an additional 1.0 million shares of our common stock for $ 126 million. </context> | us-gaap:TreasuryStockValueAcquiredCostMethod |
As of December 29, 2024, unrecognized compensation cost, related to restricted stock and ESPP shares issued to date, of $ 565 million was expected to be recognized over a weighted-average period of approximately 2.5 years. | text | 565 | monetaryItemType | text: <entity> 565 </entity> <entity type> monetaryItemType </entity type> <context> As of December 29, 2024, unrecognized compensation cost, related to restricted stock and ESPP shares issued to date, of $ 565 million was expected to be recognized over a weighted-average period of approximately 2.5 years. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
For 2024, $ 59 million was recorded in SG&A expense, $ 2 million in R&D expense, and remainder in cost of revenue. | text | 59 | monetaryItemType | text: <entity> 59 </entity> <entity type> monetaryItemType </entity type> <context> For 2024, $ 59 million was recorded in SG&A expense, $ 2 million in R&D expense, and remainder in cost of revenue. </context> | us-gaap:RestructuringSettlementAndImpairmentProvisions |
For 2024, $ 59 million was recorded in SG&A expense, $ 2 million in R&D expense, and remainder in cost of revenue. | text | 2 | monetaryItemType | text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> For 2024, $ 59 million was recorded in SG&A expense, $ 2 million in R&D expense, and remainder in cost of revenue. </context> | us-gaap:RestructuringSettlementAndImpairmentProvisions |
For 2023, $ 122 million was recorded in SG&A expense, $ 24 million in R&D expense, and remainder in cost of revenue. | text | 122 | monetaryItemType | text: <entity> 122 </entity> <entity type> monetaryItemType </entity type> <context> For 2023, $ 122 million was recorded in SG&A expense, $ 24 million in R&D expense, and remainder in cost of revenue. </context> | us-gaap:RestructuringSettlementAndImpairmentProvisions |
For 2023, $ 122 million was recorded in SG&A expense, $ 24 million in R&D expense, and remainder in cost of revenue. | text | 24 | monetaryItemType | text: <entity> 24 </entity> <entity type> monetaryItemType </entity type> <context> For 2023, $ 122 million was recorded in SG&A expense, $ 24 million in R&D expense, and remainder in cost of revenue. </context> | us-gaap:RestructuringSettlementAndImpairmentProvisions |
In 2024, we recorded right-of-use asset impairments of $ 12 million and $ 19 million related to our campus in Foster City, California and another property in San Diego, California, respectively. In 2023, we recorded right-of-use asset impairments of $ 38 million and $ 21 million related to our i3 campus in San Diego and our campus in Foster City, respectively. The impairments were determined by comparing the fair values of the impacted right-of-use assets to the carrying values of the assets as of the impairment measurement date. The fair values of the right-of-use assets were estimated using the discounted future cash flows method, which includes estimates and assumptions for future sublease rental rates that reflect current sublease market conditions, as well as discount rates. The estimates and assumptions used in our assessments represent Level 3 measurements because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. In 2024, we recorded $ 14 million of leasehold improvement impairments related to our Foster City campus and, in 2023, we recorded $ 16 million and $ 22 million of leasehold improvement impairments related to our i3 and Foster City campuses, respectively. The right-of-use asset and leasehold improvement impairments were recognized in selling, general and administrative expense. We continue to evaluate our options for the rest of our Foster City campus, for which, as of December 29, 2024, we had remaining assets, consisting primarily of right-of-use assets and leasehold improvements, of $ 100 million. | text | 12 | monetaryItemType | text: <entity> 12 </entity> <entity type> monetaryItemType </entity type> <context> In 2024, we recorded right-of-use asset impairments of $ 12 million and $ 19 million related to our campus in Foster City, California and another property in San Diego, California, respectively. In 2023, we recorded right-of-use asset impairments of $ 38 million and $ 21 million related to our i3 campus in San Diego and our campus in Foster City, respectively. The impairments were determined by comparing the fair values of the impacted right-of-use assets to the carrying values of the assets as of the impairment measurement date. The fair values of the right-of-use assets were estimated using the discounted future cash flows method, which includes estimates and assumptions for future sublease rental rates that reflect current sublease market conditions, as well as discount rates. The estimates and assumptions used in our assessments represent Level 3 measurements because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. In 2024, we recorded $ 14 million of leasehold improvement impairments related to our Foster City campus and, in 2023, we recorded $ 16 million and $ 22 million of leasehold improvement impairments related to our i3 and Foster City campuses, respectively. The right-of-use asset and leasehold improvement impairments were recognized in selling, general and administrative expense. We continue to evaluate our options for the rest of our Foster City campus, for which, as of December 29, 2024, we had remaining assets, consisting primarily of right-of-use assets and leasehold improvements, of $ 100 million. </context> | us-gaap:OperatingLeaseImpairmentLoss |
In 2024, we recorded right-of-use asset impairments of $ 12 million and $ 19 million related to our campus in Foster City, California and another property in San Diego, California, respectively. In 2023, we recorded right-of-use asset impairments of $ 38 million and $ 21 million related to our i3 campus in San Diego and our campus in Foster City, respectively. The impairments were determined by comparing the fair values of the impacted right-of-use assets to the carrying values of the assets as of the impairment measurement date. The fair values of the right-of-use assets were estimated using the discounted future cash flows method, which includes estimates and assumptions for future sublease rental rates that reflect current sublease market conditions, as well as discount rates. The estimates and assumptions used in our assessments represent Level 3 measurements because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. In 2024, we recorded $ 14 million of leasehold improvement impairments related to our Foster City campus and, in 2023, we recorded $ 16 million and $ 22 million of leasehold improvement impairments related to our i3 and Foster City campuses, respectively. The right-of-use asset and leasehold improvement impairments were recognized in selling, general and administrative expense. We continue to evaluate our options for the rest of our Foster City campus, for which, as of December 29, 2024, we had remaining assets, consisting primarily of right-of-use assets and leasehold improvements, of $ 100 million. | text | 19 | monetaryItemType | text: <entity> 19 </entity> <entity type> monetaryItemType </entity type> <context> In 2024, we recorded right-of-use asset impairments of $ 12 million and $ 19 million related to our campus in Foster City, California and another property in San Diego, California, respectively. In 2023, we recorded right-of-use asset impairments of $ 38 million and $ 21 million related to our i3 campus in San Diego and our campus in Foster City, respectively. The impairments were determined by comparing the fair values of the impacted right-of-use assets to the carrying values of the assets as of the impairment measurement date. The fair values of the right-of-use assets were estimated using the discounted future cash flows method, which includes estimates and assumptions for future sublease rental rates that reflect current sublease market conditions, as well as discount rates. The estimates and assumptions used in our assessments represent Level 3 measurements because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. In 2024, we recorded $ 14 million of leasehold improvement impairments related to our Foster City campus and, in 2023, we recorded $ 16 million and $ 22 million of leasehold improvement impairments related to our i3 and Foster City campuses, respectively. The right-of-use asset and leasehold improvement impairments were recognized in selling, general and administrative expense. We continue to evaluate our options for the rest of our Foster City campus, for which, as of December 29, 2024, we had remaining assets, consisting primarily of right-of-use assets and leasehold improvements, of $ 100 million. </context> | us-gaap:OperatingLeaseImpairmentLoss |
In 2024, we recorded right-of-use asset impairments of $ 12 million and $ 19 million related to our campus in Foster City, California and another property in San Diego, California, respectively. In 2023, we recorded right-of-use asset impairments of $ 38 million and $ 21 million related to our i3 campus in San Diego and our campus in Foster City, respectively. The impairments were determined by comparing the fair values of the impacted right-of-use assets to the carrying values of the assets as of the impairment measurement date. The fair values of the right-of-use assets were estimated using the discounted future cash flows method, which includes estimates and assumptions for future sublease rental rates that reflect current sublease market conditions, as well as discount rates. The estimates and assumptions used in our assessments represent Level 3 measurements because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. In 2024, we recorded $ 14 million of leasehold improvement impairments related to our Foster City campus and, in 2023, we recorded $ 16 million and $ 22 million of leasehold improvement impairments related to our i3 and Foster City campuses, respectively. The right-of-use asset and leasehold improvement impairments were recognized in selling, general and administrative expense. We continue to evaluate our options for the rest of our Foster City campus, for which, as of December 29, 2024, we had remaining assets, consisting primarily of right-of-use assets and leasehold improvements, of $ 100 million. | text | 38 | monetaryItemType | text: <entity> 38 </entity> <entity type> monetaryItemType </entity type> <context> In 2024, we recorded right-of-use asset impairments of $ 12 million and $ 19 million related to our campus in Foster City, California and another property in San Diego, California, respectively. In 2023, we recorded right-of-use asset impairments of $ 38 million and $ 21 million related to our i3 campus in San Diego and our campus in Foster City, respectively. The impairments were determined by comparing the fair values of the impacted right-of-use assets to the carrying values of the assets as of the impairment measurement date. The fair values of the right-of-use assets were estimated using the discounted future cash flows method, which includes estimates and assumptions for future sublease rental rates that reflect current sublease market conditions, as well as discount rates. The estimates and assumptions used in our assessments represent Level 3 measurements because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. In 2024, we recorded $ 14 million of leasehold improvement impairments related to our Foster City campus and, in 2023, we recorded $ 16 million and $ 22 million of leasehold improvement impairments related to our i3 and Foster City campuses, respectively. The right-of-use asset and leasehold improvement impairments were recognized in selling, general and administrative expense. We continue to evaluate our options for the rest of our Foster City campus, for which, as of December 29, 2024, we had remaining assets, consisting primarily of right-of-use assets and leasehold improvements, of $ 100 million. </context> | us-gaap:OperatingLeaseImpairmentLoss |
In 2024, we recorded right-of-use asset impairments of $ 12 million and $ 19 million related to our campus in Foster City, California and another property in San Diego, California, respectively. In 2023, we recorded right-of-use asset impairments of $ 38 million and $ 21 million related to our i3 campus in San Diego and our campus in Foster City, respectively. The impairments were determined by comparing the fair values of the impacted right-of-use assets to the carrying values of the assets as of the impairment measurement date. The fair values of the right-of-use assets were estimated using the discounted future cash flows method, which includes estimates and assumptions for future sublease rental rates that reflect current sublease market conditions, as well as discount rates. The estimates and assumptions used in our assessments represent Level 3 measurements because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. In 2024, we recorded $ 14 million of leasehold improvement impairments related to our Foster City campus and, in 2023, we recorded $ 16 million and $ 22 million of leasehold improvement impairments related to our i3 and Foster City campuses, respectively. The right-of-use asset and leasehold improvement impairments were recognized in selling, general and administrative expense. We continue to evaluate our options for the rest of our Foster City campus, for which, as of December 29, 2024, we had remaining assets, consisting primarily of right-of-use assets and leasehold improvements, of $ 100 million. | text | 14 | monetaryItemType | text: <entity> 14 </entity> <entity type> monetaryItemType </entity type> <context> In 2024, we recorded right-of-use asset impairments of $ 12 million and $ 19 million related to our campus in Foster City, California and another property in San Diego, California, respectively. In 2023, we recorded right-of-use asset impairments of $ 38 million and $ 21 million related to our i3 campus in San Diego and our campus in Foster City, respectively. The impairments were determined by comparing the fair values of the impacted right-of-use assets to the carrying values of the assets as of the impairment measurement date. The fair values of the right-of-use assets were estimated using the discounted future cash flows method, which includes estimates and assumptions for future sublease rental rates that reflect current sublease market conditions, as well as discount rates. The estimates and assumptions used in our assessments represent Level 3 measurements because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. In 2024, we recorded $ 14 million of leasehold improvement impairments related to our Foster City campus and, in 2023, we recorded $ 16 million and $ 22 million of leasehold improvement impairments related to our i3 and Foster City campuses, respectively. The right-of-use asset and leasehold improvement impairments were recognized in selling, general and administrative expense. We continue to evaluate our options for the rest of our Foster City campus, for which, as of December 29, 2024, we had remaining assets, consisting primarily of right-of-use assets and leasehold improvements, of $ 100 million. </context> | us-gaap:OperatingLeaseImpairmentLoss |
In 2024, we recorded right-of-use asset impairments of $ 12 million and $ 19 million related to our campus in Foster City, California and another property in San Diego, California, respectively. In 2023, we recorded right-of-use asset impairments of $ 38 million and $ 21 million related to our i3 campus in San Diego and our campus in Foster City, respectively. The impairments were determined by comparing the fair values of the impacted right-of-use assets to the carrying values of the assets as of the impairment measurement date. The fair values of the right-of-use assets were estimated using the discounted future cash flows method, which includes estimates and assumptions for future sublease rental rates that reflect current sublease market conditions, as well as discount rates. The estimates and assumptions used in our assessments represent Level 3 measurements because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. In 2024, we recorded $ 14 million of leasehold improvement impairments related to our Foster City campus and, in 2023, we recorded $ 16 million and $ 22 million of leasehold improvement impairments related to our i3 and Foster City campuses, respectively. The right-of-use asset and leasehold improvement impairments were recognized in selling, general and administrative expense. We continue to evaluate our options for the rest of our Foster City campus, for which, as of December 29, 2024, we had remaining assets, consisting primarily of right-of-use assets and leasehold improvements, of $ 100 million. | text | 16 | monetaryItemType | text: <entity> 16 </entity> <entity type> monetaryItemType </entity type> <context> In 2024, we recorded right-of-use asset impairments of $ 12 million and $ 19 million related to our campus in Foster City, California and another property in San Diego, California, respectively. In 2023, we recorded right-of-use asset impairments of $ 38 million and $ 21 million related to our i3 campus in San Diego and our campus in Foster City, respectively. The impairments were determined by comparing the fair values of the impacted right-of-use assets to the carrying values of the assets as of the impairment measurement date. The fair values of the right-of-use assets were estimated using the discounted future cash flows method, which includes estimates and assumptions for future sublease rental rates that reflect current sublease market conditions, as well as discount rates. The estimates and assumptions used in our assessments represent Level 3 measurements because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. In 2024, we recorded $ 14 million of leasehold improvement impairments related to our Foster City campus and, in 2023, we recorded $ 16 million and $ 22 million of leasehold improvement impairments related to our i3 and Foster City campuses, respectively. The right-of-use asset and leasehold improvement impairments were recognized in selling, general and administrative expense. We continue to evaluate our options for the rest of our Foster City campus, for which, as of December 29, 2024, we had remaining assets, consisting primarily of right-of-use assets and leasehold improvements, of $ 100 million. </context> | us-gaap:OperatingLeaseImpairmentLoss |
On September 3, 2024, the EU Court of Justice ruled in our favor, confirming that the European Commission had unlawfully asserted jurisdiction over our acquisition of GRAIL, and hence annulling the EU General Court’s judgment and the European Commission’s decisions accepting the referral of the GRAIL acquisition for EU merger review (the EU Court of Justice Judgment). The EU Court of Justice Judgment concludes these proceedings and is not subject to further appeals. In view of this judgment, on September 6, 2024, the European Commission issued a decision (the Withdrawal Decision) withdrawing all of its prior decisions, including (1) its July 22, 2021 decision opening an investigation of Illumina’s proposed acquisition of GRAIL, (2) its September 6, 2022 decision prohibiting Illumina’s acquisition of GRAIL, (3) its October 29, 2021 and October 28, 2022 decisions concerning interim measures, (4) the EC Divestment Decision, and (5) its July 12, 2023 decision fining Illumina € 432 million and GRAIL for closing the acquisition before approval by the European Commission. The Withdrawal Decision resolves all ongoing regulatory proceedings in the European Union. The European Commission has also been ordered to pay Illumina’s costs incurred in connection with the GRAIL-related proceedings before the EU Court of Justice and the EU General Court. | text | 432 | monetaryItemType | text: <entity> 432 </entity> <entity type> monetaryItemType </entity type> <context> On September 3, 2024, the EU Court of Justice ruled in our favor, confirming that the European Commission had unlawfully asserted jurisdiction over our acquisition of GRAIL, and hence annulling the EU General Court’s judgment and the European Commission’s decisions accepting the referral of the GRAIL acquisition for EU merger review (the EU Court of Justice Judgment). The EU Court of Justice Judgment concludes these proceedings and is not subject to further appeals. In view of this judgment, on September 6, 2024, the European Commission issued a decision (the Withdrawal Decision) withdrawing all of its prior decisions, including (1) its July 22, 2021 decision opening an investigation of Illumina’s proposed acquisition of GRAIL, (2) its September 6, 2022 decision prohibiting Illumina’s acquisition of GRAIL, (3) its October 29, 2021 and October 28, 2022 decisions concerning interim measures, (4) the EC Divestment Decision, and (5) its July 12, 2023 decision fining Illumina € 432 million and GRAIL for closing the acquisition before approval by the European Commission. The Withdrawal Decision resolves all ongoing regulatory proceedings in the European Union. The European Commission has also been ordered to pay Illumina’s costs incurred in connection with the GRAIL-related proceedings before the EU Court of Justice and the EU General Court. </context> | us-gaap:LossContingencyAccrualAtCarryingValue |
As a result of the European Commission withdrawing its previously imposed fine, we recognized a net gain of $ 481 million in Q3 2024. We recognized a gain of $ 489 million in operating expense, resulting from reversal of the accrued fine and related accrued interest, offset by a loss of $ 8 million, recognized in other expense, net, for the reversal of associated foreign currency fluctuations. The fine accrued interest at a rate of 5.5 % per annum while it was outstanding. The guarantees we provided in October 2023 to satisfy the obligation in lieu of cash payment while we appealed the European Commission’s jurisdictional and fine decisions are no longer outstanding. | text | 481 | monetaryItemType | text: <entity> 481 </entity> <entity type> monetaryItemType </entity type> <context> As a result of the European Commission withdrawing its previously imposed fine, we recognized a net gain of $ 481 million in Q3 2024. We recognized a gain of $ 489 million in operating expense, resulting from reversal of the accrued fine and related accrued interest, offset by a loss of $ 8 million, recognized in other expense, net, for the reversal of associated foreign currency fluctuations. The fine accrued interest at a rate of 5.5 % per annum while it was outstanding. The guarantees we provided in October 2023 to satisfy the obligation in lieu of cash payment while we appealed the European Commission’s jurisdictional and fine decisions are no longer outstanding. </context> | us-gaap:GainLossRelatedToLitigationSettlement |
As a result of the European Commission withdrawing its previously imposed fine, we recognized a net gain of $ 481 million in Q3 2024. We recognized a gain of $ 489 million in operating expense, resulting from reversal of the accrued fine and related accrued interest, offset by a loss of $ 8 million, recognized in other expense, net, for the reversal of associated foreign currency fluctuations. The fine accrued interest at a rate of 5.5 % per annum while it was outstanding. The guarantees we provided in October 2023 to satisfy the obligation in lieu of cash payment while we appealed the European Commission’s jurisdictional and fine decisions are no longer outstanding. | text | 489 | monetaryItemType | text: <entity> 489 </entity> <entity type> monetaryItemType </entity type> <context> As a result of the European Commission withdrawing its previously imposed fine, we recognized a net gain of $ 481 million in Q3 2024. We recognized a gain of $ 489 million in operating expense, resulting from reversal of the accrued fine and related accrued interest, offset by a loss of $ 8 million, recognized in other expense, net, for the reversal of associated foreign currency fluctuations. The fine accrued interest at a rate of 5.5 % per annum while it was outstanding. The guarantees we provided in October 2023 to satisfy the obligation in lieu of cash payment while we appealed the European Commission’s jurisdictional and fine decisions are no longer outstanding. </context> | us-gaap:LitigationSettlementGain |
As a result of the European Commission withdrawing its previously imposed fine, we recognized a net gain of $ 481 million in Q3 2024. We recognized a gain of $ 489 million in operating expense, resulting from reversal of the accrued fine and related accrued interest, offset by a loss of $ 8 million, recognized in other expense, net, for the reversal of associated foreign currency fluctuations. The fine accrued interest at a rate of 5.5 % per annum while it was outstanding. The guarantees we provided in October 2023 to satisfy the obligation in lieu of cash payment while we appealed the European Commission’s jurisdictional and fine decisions are no longer outstanding. | text | 8 | monetaryItemType | text: <entity> 8 </entity> <entity type> monetaryItemType </entity type> <context> As a result of the European Commission withdrawing its previously imposed fine, we recognized a net gain of $ 481 million in Q3 2024. We recognized a gain of $ 489 million in operating expense, resulting from reversal of the accrued fine and related accrued interest, offset by a loss of $ 8 million, recognized in other expense, net, for the reversal of associated foreign currency fluctuations. The fine accrued interest at a rate of 5.5 % per annum while it was outstanding. The guarantees we provided in October 2023 to satisfy the obligation in lieu of cash payment while we appealed the European Commission’s jurisdictional and fine decisions are no longer outstanding. </context> | us-gaap:LitigationSettlementLoss |
On November 11, 2023, the first of three securities class action complaints was filed against Illumina and certain of its current and former executive officers in the United States District Court for the Southern District of California. The first-filed case is captioned | text | three | integerItemType | text: <entity> three </entity> <entity type> integerItemType </entity type> <context> On November 11, 2023, the first of three securities class action complaints was filed against Illumina and certain of its current and former executive officers in the United States District Court for the Southern District of California. The first-filed case is captioned </context> | us-gaap:LossContingencyNewClaimsFiledNumber |
As previously disclosed, we were engaged in litigation in various U.S. jurisdictions with BGI Genomics Co. Ltd (BGI) and certain of its affiliates, including Complete Genomics, Inc. (CGI) since June of 2019. On July 14, 2022, we entered into a Settlement and License Agreement with BGI and CGI (the Agreement). Pursuant to the terms of the Agreement, we agreed to pay CGI a one time payment of $ 325 million. We allocated the $ 325 million payment on a relative fair value basis, resulting in $ 180 million capitalized as an intangible asset in 2022 for the value of the license, which is amortized over a period of 6.5 years on a straight-line basis, $ 150 million allocated to the release of past damages claimed, and a $ 5 million gain for damages awarded to us. The fair value of the license was estimated using a discounted cash flow model, which included assumptions for projected revenues covered by the license, an estimated royalty rate and a discount rate. The fair value of the past damages claimed was estimated based on applicable historical revenues and an estimated royalty rate. These inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. | text | 325 | monetaryItemType | text: <entity> 325 </entity> <entity type> monetaryItemType </entity type> <context> As previously disclosed, we were engaged in litigation in various U.S. jurisdictions with BGI Genomics Co. Ltd (BGI) and certain of its affiliates, including Complete Genomics, Inc. (CGI) since June of 2019. On July 14, 2022, we entered into a Settlement and License Agreement with BGI and CGI (the Agreement). Pursuant to the terms of the Agreement, we agreed to pay CGI a one time payment of $ 325 million. We allocated the $ 325 million payment on a relative fair value basis, resulting in $ 180 million capitalized as an intangible asset in 2022 for the value of the license, which is amortized over a period of 6.5 years on a straight-line basis, $ 150 million allocated to the release of past damages claimed, and a $ 5 million gain for damages awarded to us. The fair value of the license was estimated using a discounted cash flow model, which included assumptions for projected revenues covered by the license, an estimated royalty rate and a discount rate. The fair value of the past damages claimed was estimated based on applicable historical revenues and an estimated royalty rate. These inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. </context> | us-gaap:PaymentsForLegalSettlements |
As previously disclosed, we were engaged in litigation in various U.S. jurisdictions with BGI Genomics Co. Ltd (BGI) and certain of its affiliates, including Complete Genomics, Inc. (CGI) since June of 2019. On July 14, 2022, we entered into a Settlement and License Agreement with BGI and CGI (the Agreement). Pursuant to the terms of the Agreement, we agreed to pay CGI a one time payment of $ 325 million. We allocated the $ 325 million payment on a relative fair value basis, resulting in $ 180 million capitalized as an intangible asset in 2022 for the value of the license, which is amortized over a period of 6.5 years on a straight-line basis, $ 150 million allocated to the release of past damages claimed, and a $ 5 million gain for damages awarded to us. The fair value of the license was estimated using a discounted cash flow model, which included assumptions for projected revenues covered by the license, an estimated royalty rate and a discount rate. The fair value of the past damages claimed was estimated based on applicable historical revenues and an estimated royalty rate. These inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. | text | 5 | monetaryItemType | text: <entity> 5 </entity> <entity type> monetaryItemType </entity type> <context> As previously disclosed, we were engaged in litigation in various U.S. jurisdictions with BGI Genomics Co. Ltd (BGI) and certain of its affiliates, including Complete Genomics, Inc. (CGI) since June of 2019. On July 14, 2022, we entered into a Settlement and License Agreement with BGI and CGI (the Agreement). Pursuant to the terms of the Agreement, we agreed to pay CGI a one time payment of $ 325 million. We allocated the $ 325 million payment on a relative fair value basis, resulting in $ 180 million capitalized as an intangible asset in 2022 for the value of the license, which is amortized over a period of 6.5 years on a straight-line basis, $ 150 million allocated to the release of past damages claimed, and a $ 5 million gain for damages awarded to us. The fair value of the license was estimated using a discounted cash flow model, which included assumptions for projected revenues covered by the license, an estimated royalty rate and a discount rate. The fair value of the past damages claimed was estimated based on applicable historical revenues and an estimated royalty rate. These inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. </context> | us-gaap:FormerGainContingencyRecognizedInCurrentPeriod |
A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence, including operating results and forecasted ranges of future taxable income. Based on the available evidence as of December 29, 2024, we were not able to conclude it is more likely than not certain deferred tax assets will be realized. Therefore, a valuation allowance of $ 278 million was recorded against certain U.S. and foreign deferred tax assets. | text | 278 | monetaryItemType | text: <entity> 278 </entity> <entity type> monetaryItemType </entity type> <context> A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction-by-jurisdiction basis and includes a review of all available positive and negative evidence, including operating results and forecasted ranges of future taxable income. Based on the available evidence as of December 29, 2024, we were not able to conclude it is more likely than not certain deferred tax assets will be realized. Therefore, a valuation allowance of $ 278 million was recorded against certain U.S. and foreign deferred tax assets. </context> | us-gaap:DeferredTaxAssetsValuationAllowance |
As of December 29, 2024, we had net operating loss carryforwards for federal and state tax purposes of $ 74 million and $ 1,872 million, respectively, which will begin to expire in 2036 and 2025, respectively, unless utilized prior. We also had federal and state tax credit carryforwards of $ 140 million and $ 239 million, which will begin to expire in 2031 and 2027, respectively, unless utilized prior. | text | 74 | monetaryItemType | text: <entity> 74 </entity> <entity type> monetaryItemType </entity type> <context> As of December 29, 2024, we had net operating loss carryforwards for federal and state tax purposes of $ 74 million and $ 1,872 million, respectively, which will begin to expire in 2036 and 2025, respectively, unless utilized prior. We also had federal and state tax credit carryforwards of $ 140 million and $ 239 million, which will begin to expire in 2031 and 2027, respectively, unless utilized prior. </context> | us-gaap:OperatingLossCarryforwards |
As of December 29, 2024, we had net operating loss carryforwards for federal and state tax purposes of $ 74 million and $ 1,872 million, respectively, which will begin to expire in 2036 and 2025, respectively, unless utilized prior. We also had federal and state tax credit carryforwards of $ 140 million and $ 239 million, which will begin to expire in 2031 and 2027, respectively, unless utilized prior. | text | 1872 | monetaryItemType | text: <entity> 1872 </entity> <entity type> monetaryItemType </entity type> <context> As of December 29, 2024, we had net operating loss carryforwards for federal and state tax purposes of $ 74 million and $ 1,872 million, respectively, which will begin to expire in 2036 and 2025, respectively, unless utilized prior. We also had federal and state tax credit carryforwards of $ 140 million and $ 239 million, which will begin to expire in 2031 and 2027, respectively, unless utilized prior. </context> | us-gaap:OperatingLossCarryforwards |
As of December 29, 2024, we had net operating loss carryforwards for federal and state tax purposes of $ 74 million and $ 1,872 million, respectively, which will begin to expire in 2036 and 2025, respectively, unless utilized prior. We also had federal and state tax credit carryforwards of $ 140 million and $ 239 million, which will begin to expire in 2031 and 2027, respectively, unless utilized prior. | text | 140 | monetaryItemType | text: <entity> 140 </entity> <entity type> monetaryItemType </entity type> <context> As of December 29, 2024, we had net operating loss carryforwards for federal and state tax purposes of $ 74 million and $ 1,872 million, respectively, which will begin to expire in 2036 and 2025, respectively, unless utilized prior. We also had federal and state tax credit carryforwards of $ 140 million and $ 239 million, which will begin to expire in 2031 and 2027, respectively, unless utilized prior. </context> | us-gaap:TaxCreditCarryforwardAmount |
As of December 29, 2024, we had net operating loss carryforwards for federal and state tax purposes of $ 74 million and $ 1,872 million, respectively, which will begin to expire in 2036 and 2025, respectively, unless utilized prior. We also had federal and state tax credit carryforwards of $ 140 million and $ 239 million, which will begin to expire in 2031 and 2027, respectively, unless utilized prior. | text | 239 | monetaryItemType | text: <entity> 239 </entity> <entity type> monetaryItemType </entity type> <context> As of December 29, 2024, we had net operating loss carryforwards for federal and state tax purposes of $ 74 million and $ 1,872 million, respectively, which will begin to expire in 2036 and 2025, respectively, unless utilized prior. We also had federal and state tax credit carryforwards of $ 140 million and $ 239 million, which will begin to expire in 2031 and 2027, respectively, unless utilized prior. </context> | us-gaap:TaxCreditCarryforwardAmount |
Our manufacturing operations in Singapore operate under various tax holidays and incentives, which will begin to expire in 2028. These tax holidays and incentives resulted in a $ 33 million, $ 75 million, and $ 56 million decrease to the provision for income taxes in 2024, 2023, and 2022, respectively. These tax holidays and incentives resulted in a decrease in diluted loss per share of $ 0.20 , $ 0.47 , and $ 0.35 , in 2024, 2023, and 2022, respectively. | text | 33 | monetaryItemType | text: <entity> 33 </entity> <entity type> monetaryItemType </entity type> <context> Our manufacturing operations in Singapore operate under various tax holidays and incentives, which will begin to expire in 2028. These tax holidays and incentives resulted in a $ 33 million, $ 75 million, and $ 56 million decrease to the provision for income taxes in 2024, 2023, and 2022, respectively. These tax holidays and incentives resulted in a decrease in diluted loss per share of $ 0.20 , $ 0.47 , and $ 0.35 , in 2024, 2023, and 2022, respectively. </context> | us-gaap:IncomeTaxHolidayAggregateDollarAmount |
Our manufacturing operations in Singapore operate under various tax holidays and incentives, which will begin to expire in 2028. These tax holidays and incentives resulted in a $ 33 million, $ 75 million, and $ 56 million decrease to the provision for income taxes in 2024, 2023, and 2022, respectively. These tax holidays and incentives resulted in a decrease in diluted loss per share of $ 0.20 , $ 0.47 , and $ 0.35 , in 2024, 2023, and 2022, respectively. | text | 75 | monetaryItemType | text: <entity> 75 </entity> <entity type> monetaryItemType </entity type> <context> Our manufacturing operations in Singapore operate under various tax holidays and incentives, which will begin to expire in 2028. These tax holidays and incentives resulted in a $ 33 million, $ 75 million, and $ 56 million decrease to the provision for income taxes in 2024, 2023, and 2022, respectively. These tax holidays and incentives resulted in a decrease in diluted loss per share of $ 0.20 , $ 0.47 , and $ 0.35 , in 2024, 2023, and 2022, respectively. </context> | us-gaap:IncomeTaxHolidayAggregateDollarAmount |
Our manufacturing operations in Singapore operate under various tax holidays and incentives, which will begin to expire in 2028. These tax holidays and incentives resulted in a $ 33 million, $ 75 million, and $ 56 million decrease to the provision for income taxes in 2024, 2023, and 2022, respectively. These tax holidays and incentives resulted in a decrease in diluted loss per share of $ 0.20 , $ 0.47 , and $ 0.35 , in 2024, 2023, and 2022, respectively. | text | 56 | monetaryItemType | text: <entity> 56 </entity> <entity type> monetaryItemType </entity type> <context> Our manufacturing operations in Singapore operate under various tax holidays and incentives, which will begin to expire in 2028. These tax holidays and incentives resulted in a $ 33 million, $ 75 million, and $ 56 million decrease to the provision for income taxes in 2024, 2023, and 2022, respectively. These tax holidays and incentives resulted in a decrease in diluted loss per share of $ 0.20 , $ 0.47 , and $ 0.35 , in 2024, 2023, and 2022, respectively. </context> | us-gaap:IncomeTaxHolidayAggregateDollarAmount |
Our manufacturing operations in Singapore operate under various tax holidays and incentives, which will begin to expire in 2028. These tax holidays and incentives resulted in a $ 33 million, $ 75 million, and $ 56 million decrease to the provision for income taxes in 2024, 2023, and 2022, respectively. These tax holidays and incentives resulted in a decrease in diluted loss per share of $ 0.20 , $ 0.47 , and $ 0.35 , in 2024, 2023, and 2022, respectively. | text | 0.20 | perShareItemType | text: <entity> 0.20 </entity> <entity type> perShareItemType </entity type> <context> Our manufacturing operations in Singapore operate under various tax holidays and incentives, which will begin to expire in 2028. These tax holidays and incentives resulted in a $ 33 million, $ 75 million, and $ 56 million decrease to the provision for income taxes in 2024, 2023, and 2022, respectively. These tax holidays and incentives resulted in a decrease in diluted loss per share of $ 0.20 , $ 0.47 , and $ 0.35 , in 2024, 2023, and 2022, respectively. </context> | us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare |
Our manufacturing operations in Singapore operate under various tax holidays and incentives, which will begin to expire in 2028. These tax holidays and incentives resulted in a $ 33 million, $ 75 million, and $ 56 million decrease to the provision for income taxes in 2024, 2023, and 2022, respectively. These tax holidays and incentives resulted in a decrease in diluted loss per share of $ 0.20 , $ 0.47 , and $ 0.35 , in 2024, 2023, and 2022, respectively. | text | 0.47 | perShareItemType | text: <entity> 0.47 </entity> <entity type> perShareItemType </entity type> <context> Our manufacturing operations in Singapore operate under various tax holidays and incentives, which will begin to expire in 2028. These tax holidays and incentives resulted in a $ 33 million, $ 75 million, and $ 56 million decrease to the provision for income taxes in 2024, 2023, and 2022, respectively. These tax holidays and incentives resulted in a decrease in diluted loss per share of $ 0.20 , $ 0.47 , and $ 0.35 , in 2024, 2023, and 2022, respectively. </context> | us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare |
Our manufacturing operations in Singapore operate under various tax holidays and incentives, which will begin to expire in 2028. These tax holidays and incentives resulted in a $ 33 million, $ 75 million, and $ 56 million decrease to the provision for income taxes in 2024, 2023, and 2022, respectively. These tax holidays and incentives resulted in a decrease in diluted loss per share of $ 0.20 , $ 0.47 , and $ 0.35 , in 2024, 2023, and 2022, respectively. | text | 0.35 | perShareItemType | text: <entity> 0.35 </entity> <entity type> perShareItemType </entity type> <context> Our manufacturing operations in Singapore operate under various tax holidays and incentives, which will begin to expire in 2028. These tax holidays and incentives resulted in a $ 33 million, $ 75 million, and $ 56 million decrease to the provision for income taxes in 2024, 2023, and 2022, respectively. These tax holidays and incentives resulted in a decrease in diluted loss per share of $ 0.20 , $ 0.47 , and $ 0.35 , in 2024, 2023, and 2022, respectively. </context> | us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare |
As of December 29, 2024, we asserted that $ 1,806 million of foreign earnings would not be indefinitely reinvested, and accordingly, recorded a deferred tax liability of $ 24 million. | text | 1806 | monetaryItemType | text: <entity> 1806 </entity> <entity type> monetaryItemType </entity type> <context> As of December 29, 2024, we asserted that $ 1,806 million of foreign earnings would not be indefinitely reinvested, and accordingly, recorded a deferred tax liability of $ 24 million. </context> | us-gaap:UndistributedEarningsOfForeignSubsidiaries |
As of December 29, 2024, we asserted that $ 1,806 million of foreign earnings would not be indefinitely reinvested, and accordingly, recorded a deferred tax liability of $ 24 million. | text | 24 | monetaryItemType | text: <entity> 24 </entity> <entity type> monetaryItemType </entity type> <context> As of December 29, 2024, we asserted that $ 1,806 million of foreign earnings would not be indefinitely reinvested, and accordingly, recorded a deferred tax liability of $ 24 million. </context> | us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings |
Included in the balance of uncertain tax positions as of December 29, 2024 and December 31, 2023, was $ 202 million and $ 156 million, respectively, of net unrecognized tax benefits that, if recognized, would reduce the effective income tax rate in future periods. | text | 202 | monetaryItemType | text: <entity> 202 </entity> <entity type> monetaryItemType </entity type> <context> Included in the balance of uncertain tax positions as of December 29, 2024 and December 31, 2023, was $ 202 million and $ 156 million, respectively, of net unrecognized tax benefits that, if recognized, would reduce the effective income tax rate in future periods. </context> | us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate |
Included in the balance of uncertain tax positions as of December 29, 2024 and December 31, 2023, was $ 202 million and $ 156 million, respectively, of net unrecognized tax benefits that, if recognized, would reduce the effective income tax rate in future periods. | text | 156 | monetaryItemType | text: <entity> 156 </entity> <entity type> monetaryItemType </entity type> <context> Included in the balance of uncertain tax positions as of December 29, 2024 and December 31, 2023, was $ 202 million and $ 156 million, respectively, of net unrecognized tax benefits that, if recognized, would reduce the effective income tax rate in future periods. </context> | us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate |
Any interest and penalties related to uncertain tax positions are reflected in the provision for income taxes. We recognized expense of $ 6 million and $ 2 million in 2024 and 2023, respectively, and income of $ 3 million in 2022, related to potential interest and penalties on uncertain tax positions. We recorded a liability for potential interest and penalties of $ 13 million and $ 6 million as of December 29, 2024 and December 31, 2023, respectively. | text | 6 | monetaryItemType | text: <entity> 6 </entity> <entity type> monetaryItemType </entity type> <context> Any interest and penalties related to uncertain tax positions are reflected in the provision for income taxes. We recognized expense of $ 6 million and $ 2 million in 2024 and 2023, respectively, and income of $ 3 million in 2022, related to potential interest and penalties on uncertain tax positions. We recorded a liability for potential interest and penalties of $ 13 million and $ 6 million as of December 29, 2024 and December 31, 2023, respectively. </context> | us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense |
Any interest and penalties related to uncertain tax positions are reflected in the provision for income taxes. We recognized expense of $ 6 million and $ 2 million in 2024 and 2023, respectively, and income of $ 3 million in 2022, related to potential interest and penalties on uncertain tax positions. We recorded a liability for potential interest and penalties of $ 13 million and $ 6 million as of December 29, 2024 and December 31, 2023, respectively. | text | 2 | monetaryItemType | text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> Any interest and penalties related to uncertain tax positions are reflected in the provision for income taxes. We recognized expense of $ 6 million and $ 2 million in 2024 and 2023, respectively, and income of $ 3 million in 2022, related to potential interest and penalties on uncertain tax positions. We recorded a liability for potential interest and penalties of $ 13 million and $ 6 million as of December 29, 2024 and December 31, 2023, respectively. </context> | us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense |
Any interest and penalties related to uncertain tax positions are reflected in the provision for income taxes. We recognized expense of $ 6 million and $ 2 million in 2024 and 2023, respectively, and income of $ 3 million in 2022, related to potential interest and penalties on uncertain tax positions. We recorded a liability for potential interest and penalties of $ 13 million and $ 6 million as of December 29, 2024 and December 31, 2023, respectively. | text | 3 | monetaryItemType | text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> Any interest and penalties related to uncertain tax positions are reflected in the provision for income taxes. We recognized expense of $ 6 million and $ 2 million in 2024 and 2023, respectively, and income of $ 3 million in 2022, related to potential interest and penalties on uncertain tax positions. We recorded a liability for potential interest and penalties of $ 13 million and $ 6 million as of December 29, 2024 and December 31, 2023, respectively. </context> | us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense |
Any interest and penalties related to uncertain tax positions are reflected in the provision for income taxes. We recognized expense of $ 6 million and $ 2 million in 2024 and 2023, respectively, and income of $ 3 million in 2022, related to potential interest and penalties on uncertain tax positions. We recorded a liability for potential interest and penalties of $ 13 million and $ 6 million as of December 29, 2024 and December 31, 2023, respectively. | text | 13 | monetaryItemType | text: <entity> 13 </entity> <entity type> monetaryItemType </entity type> <context> Any interest and penalties related to uncertain tax positions are reflected in the provision for income taxes. We recognized expense of $ 6 million and $ 2 million in 2024 and 2023, respectively, and income of $ 3 million in 2022, related to potential interest and penalties on uncertain tax positions. We recorded a liability for potential interest and penalties of $ 13 million and $ 6 million as of December 29, 2024 and December 31, 2023, respectively. </context> | us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued |
Any interest and penalties related to uncertain tax positions are reflected in the provision for income taxes. We recognized expense of $ 6 million and $ 2 million in 2024 and 2023, respectively, and income of $ 3 million in 2022, related to potential interest and penalties on uncertain tax positions. We recorded a liability for potential interest and penalties of $ 13 million and $ 6 million as of December 29, 2024 and December 31, 2023, respectively. | text | 6 | monetaryItemType | text: <entity> 6 </entity> <entity type> monetaryItemType </entity type> <context> Any interest and penalties related to uncertain tax positions are reflected in the provision for income taxes. We recognized expense of $ 6 million and $ 2 million in 2024 and 2023, respectively, and income of $ 3 million in 2022, related to potential interest and penalties on uncertain tax positions. We recorded a liability for potential interest and penalties of $ 13 million and $ 6 million as of December 29, 2024 and December 31, 2023, respectively. </context> | us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued |
We have a 401(k) savings plan covering substantially all of our employees in the United States. Our contributions to the plan are discretionary. During 2024, 2023, and 2022, we made matching contributions of $ 34 million, $ 36 million, and $ 30 million, respectively. | text | 34 | monetaryItemType | text: <entity> 34 </entity> <entity type> monetaryItemType </entity type> <context> We have a 401(k) savings plan covering substantially all of our employees in the United States. Our contributions to the plan are discretionary. During 2024, 2023, and 2022, we made matching contributions of $ 34 million, $ 36 million, and $ 30 million, respectively. </context> | us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount |
We have a 401(k) savings plan covering substantially all of our employees in the United States. Our contributions to the plan are discretionary. During 2024, 2023, and 2022, we made matching contributions of $ 34 million, $ 36 million, and $ 30 million, respectively. | text | 36 | monetaryItemType | text: <entity> 36 </entity> <entity type> monetaryItemType </entity type> <context> We have a 401(k) savings plan covering substantially all of our employees in the United States. Our contributions to the plan are discretionary. During 2024, 2023, and 2022, we made matching contributions of $ 34 million, $ 36 million, and $ 30 million, respectively. </context> | us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount |
We have a 401(k) savings plan covering substantially all of our employees in the United States. Our contributions to the plan are discretionary. During 2024, 2023, and 2022, we made matching contributions of $ 34 million, $ 36 million, and $ 30 million, respectively. | text | 30 | monetaryItemType | text: <entity> 30 </entity> <entity type> monetaryItemType </entity type> <context> We have a 401(k) savings plan covering substantially all of our employees in the United States. Our contributions to the plan are discretionary. During 2024, 2023, and 2022, we made matching contributions of $ 34 million, $ 36 million, and $ 30 million, respectively. </context> | us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount |
As of December 29, 2024, we have one reportable segment, Core Illumina. Prior to the Spin-Off of GRAIL, on June 24, 2024, our reportable segments included both Core Illumina and GRAIL. See note | text | one | integerItemType | text: <entity> one </entity> <entity type> integerItemType </entity type> <context> As of December 29, 2024, we have one reportable segment, Core Illumina. Prior to the Spin-Off of GRAIL, on June 24, 2024, our reportable segments included both Core Illumina and GRAIL. See note </context> | us-gaap:NumberOfReportableSegments |
Core Illumina revenue for 2024, 2023, and 2022 included intercompany revenue of $ 15 million, $ 26 million, and $ 24 million, respectively. | text | 15 | monetaryItemType | text: <entity> 15 </entity> <entity type> monetaryItemType </entity type> <context> Core Illumina revenue for 2024, 2023, and 2022 included intercompany revenue of $ 15 million, $ 26 million, and $ 24 million, respectively. </context> | us-gaap:CostOfRevenue |
Core Illumina revenue for 2024, 2023, and 2022 included intercompany revenue of $ 15 million, $ 26 million, and $ 24 million, respectively. | text | 26 | monetaryItemType | text: <entity> 26 </entity> <entity type> monetaryItemType </entity type> <context> Core Illumina revenue for 2024, 2023, and 2022 included intercompany revenue of $ 15 million, $ 26 million, and $ 24 million, respectively. </context> | us-gaap:CostOfRevenue |
Core Illumina revenue for 2024, 2023, and 2022 included intercompany revenue of $ 15 million, $ 26 million, and $ 24 million, respectively. | text | 24 | monetaryItemType | text: <entity> 24 </entity> <entity type> monetaryItemType </entity type> <context> Core Illumina revenue for 2024, 2023, and 2022 included intercompany revenue of $ 15 million, $ 26 million, and $ 24 million, respectively. </context> | us-gaap:CostOfRevenue |
Represents net income less (i) earnings allocated to participating share awards of $ 76 million, $ 64 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively, and (ii) dividends on preferred shares of $ 58 million, $ 58 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 76 | monetaryItemType | text: <entity> 76 </entity> <entity type> monetaryItemType </entity type> <context> Represents net income less (i) earnings allocated to participating share awards of $ 76 million, $ 64 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively, and (ii) dividends on preferred shares of $ 58 million, $ 58 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic |
Represents net income less (i) earnings allocated to participating share awards of $ 76 million, $ 64 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively, and (ii) dividends on preferred shares of $ 58 million, $ 58 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 64 | monetaryItemType | text: <entity> 64 </entity> <entity type> monetaryItemType </entity type> <context> Represents net income less (i) earnings allocated to participating share awards of $ 76 million, $ 64 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively, and (ii) dividends on preferred shares of $ 58 million, $ 58 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic |
Represents net income less (i) earnings allocated to participating share awards of $ 76 million, $ 64 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively, and (ii) dividends on preferred shares of $ 58 million, $ 58 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 57 | monetaryItemType | text: <entity> 57 </entity> <entity type> monetaryItemType </entity type> <context> Represents net income less (i) earnings allocated to participating share awards of $ 76 million, $ 64 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively, and (ii) dividends on preferred shares of $ 58 million, $ 58 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic |
Represents net income less (i) earnings allocated to participating share awards of $ 76 million, $ 64 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively, and (ii) dividends on preferred shares of $ 58 million, $ 58 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 58 | monetaryItemType | text: <entity> 58 </entity> <entity type> monetaryItemType </entity type> <context> Represents net income less (i) earnings allocated to participating share awards of $ 76 million, $ 64 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively, and (ii) dividends on preferred shares of $ 58 million, $ 58 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:DividendsPreferredStock |
Represents net income less (i) earnings allocated to participating share awards of $ 76 million, $ 64 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively, and (ii) dividends on preferred shares of $ 58 million, $ 58 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 57 | monetaryItemType | text: <entity> 57 </entity> <entity type> monetaryItemType </entity type> <context> Represents net income less (i) earnings allocated to participating share awards of $ 76 million, $ 64 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively, and (ii) dividends on preferred shares of $ 58 million, $ 58 million and $ 57 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:DividendsPreferredStock |
Net income taxes paid during 2024, 2023 and 2022 were $ 3.6 billion, $ 3.3 billion and $ 3.0 billion, respectively, and interest paid primarily related to Debt and Customer deposits for the same periods were $ 8.2 billion, $ 6.4 billion and $ 2.2 billion, respectively. | text | 3.6 | monetaryItemType | text: <entity> 3.6 </entity> <entity type> monetaryItemType </entity type> <context> Net income taxes paid during 2024, 2023 and 2022 were $ 3.6 billion, $ 3.3 billion and $ 3.0 billion, respectively, and interest paid primarily related to Debt and Customer deposits for the same periods were $ 8.2 billion, $ 6.4 billion and $ 2.2 billion, respectively. </context> | us-gaap:IncomeTaxesPaidNet |
Net income taxes paid during 2024, 2023 and 2022 were $ 3.6 billion, $ 3.3 billion and $ 3.0 billion, respectively, and interest paid primarily related to Debt and Customer deposits for the same periods were $ 8.2 billion, $ 6.4 billion and $ 2.2 billion, respectively. | text | 3.3 | monetaryItemType | text: <entity> 3.3 </entity> <entity type> monetaryItemType </entity type> <context> Net income taxes paid during 2024, 2023 and 2022 were $ 3.6 billion, $ 3.3 billion and $ 3.0 billion, respectively, and interest paid primarily related to Debt and Customer deposits for the same periods were $ 8.2 billion, $ 6.4 billion and $ 2.2 billion, respectively. </context> | us-gaap:IncomeTaxesPaidNet |
Net income taxes paid during 2024, 2023 and 2022 were $ 3.6 billion, $ 3.3 billion and $ 3.0 billion, respectively, and interest paid primarily related to Debt and Customer deposits for the same periods were $ 8.2 billion, $ 6.4 billion and $ 2.2 billion, respectively. | text | 3.0 | monetaryItemType | text: <entity> 3.0 </entity> <entity type> monetaryItemType </entity type> <context> Net income taxes paid during 2024, 2023 and 2022 were $ 3.6 billion, $ 3.3 billion and $ 3.0 billion, respectively, and interest paid primarily related to Debt and Customer deposits for the same periods were $ 8.2 billion, $ 6.4 billion and $ 2.2 billion, respectively. </context> | us-gaap:IncomeTaxesPaidNet |
Net income taxes paid during 2024, 2023 and 2022 were $ 3.6 billion, $ 3.3 billion and $ 3.0 billion, respectively, and interest paid primarily related to Debt and Customer deposits for the same periods were $ 8.2 billion, $ 6.4 billion and $ 2.2 billion, respectively. | text | 8.2 | monetaryItemType | text: <entity> 8.2 </entity> <entity type> monetaryItemType </entity type> <context> Net income taxes paid during 2024, 2023 and 2022 were $ 3.6 billion, $ 3.3 billion and $ 3.0 billion, respectively, and interest paid primarily related to Debt and Customer deposits for the same periods were $ 8.2 billion, $ 6.4 billion and $ 2.2 billion, respectively. </context> | us-gaap:InterestPaidNet |
Net income taxes paid during 2024, 2023 and 2022 were $ 3.6 billion, $ 3.3 billion and $ 3.0 billion, respectively, and interest paid primarily related to Debt and Customer deposits for the same periods were $ 8.2 billion, $ 6.4 billion and $ 2.2 billion, respectively. | text | 6.4 | monetaryItemType | text: <entity> 6.4 </entity> <entity type> monetaryItemType </entity type> <context> Net income taxes paid during 2024, 2023 and 2022 were $ 3.6 billion, $ 3.3 billion and $ 3.0 billion, respectively, and interest paid primarily related to Debt and Customer deposits for the same periods were $ 8.2 billion, $ 6.4 billion and $ 2.2 billion, respectively. </context> | us-gaap:InterestPaidNet |
Net income taxes paid during 2024, 2023 and 2022 were $ 3.6 billion, $ 3.3 billion and $ 3.0 billion, respectively, and interest paid primarily related to Debt and Customer deposits for the same periods were $ 8.2 billion, $ 6.4 billion and $ 2.2 billion, respectively. | text | 2.2 | monetaryItemType | text: <entity> 2.2 </entity> <entity type> monetaryItemType </entity type> <context> Net income taxes paid during 2024, 2023 and 2022 were $ 3.6 billion, $ 3.3 billion and $ 3.0 billion, respectively, and interest paid primarily related to Debt and Customer deposits for the same periods were $ 8.2 billion, $ 6.4 billion and $ 2.2 billion, respectively. </context> | us-gaap:InterestPaidNet |
On May 1, 2024, we completed the previously announced transaction to sell fraud prevention solutions provider Accertify, Inc. (Accertify), a wholly owned subsidiary we acquired in 2010, the operations of which were reported within the Global Merchant and Network Services (GMNS) segment. The transaction resulted in a gain of $ 531 million ($ 479 million after tax), which was reported as a reduction to Other expense in the second quarter of 2024. Prior to the completion of the transaction, the carrying amount of Accertify’s net assets were not material to the Company’s financial position. | text | 531 | monetaryItemType | text: <entity> 531 </entity> <entity type> monetaryItemType </entity type> <context> On May 1, 2024, we completed the previously announced transaction to sell fraud prevention solutions provider Accertify, Inc. (Accertify), a wholly owned subsidiary we acquired in 2010, the operations of which were reported within the Global Merchant and Network Services (GMNS) segment. The transaction resulted in a gain of $ 531 million ($ 479 million after tax), which was reported as a reduction to Other expense in the second quarter of 2024. Prior to the completion of the transaction, the carrying amount of Accertify’s net assets were not material to the Company’s financial position. </context> | us-gaap:GainLossOnSaleOfBusiness |
Effective December 1, 2024, we reclassified $ 758 million of Card Member loans related to the Lowe’s small business cobrand portfolio to Card Member loans held for sale on the Consolidated Balance Sheets and reversed $ 49 million of associated reserves for credit losses. | text | 758 | monetaryItemType | text: <entity> 758 </entity> <entity type> monetaryItemType </entity type> <context> Effective December 1, 2024, we reclassified $ 758 million of Card Member loans related to the Lowe’s small business cobrand portfolio to Card Member loans held for sale on the Consolidated Balance Sheets and reversed $ 49 million of associated reserves for credit losses. </context> | us-gaap:LoansReceivableHeldForSaleAmount |
Effective December 1, 2024, we reclassified $ 758 million of Card Member loans related to the Lowe’s small business cobrand portfolio to Card Member loans held for sale on the Consolidated Balance Sheets and reversed $ 49 million of associated reserves for credit losses. | text | 49 | monetaryItemType | text: <entity> 49 </entity> <entity type> monetaryItemType </entity type> <context> Effective December 1, 2024, we reclassified $ 758 million of Card Member loans related to the Lowe’s small business cobrand portfolio to Card Member loans held for sale on the Consolidated Balance Sheets and reversed $ 49 million of associated reserves for credit losses. </context> | us-gaap:ProvisionForLoanLossesExpensed |
Includes approximately $ 28.3 billion and $ 28.6 billion of gross Card Member loans available to settle obligations of a consolidated VIE as of December 31, 2024 and 2023, respectively. | text | 28.3 | monetaryItemType | text: <entity> 28.3 </entity> <entity type> monetaryItemType </entity type> <context> Includes approximately $ 28.3 billion and $ 28.6 billion of gross Card Member loans available to settle obligations of a consolidated VIE as of December 31, 2024 and 2023, respectively. </context> | us-gaap:NotesReceivableGross |
Includes approximately $ 28.3 billion and $ 28.6 billion of gross Card Member loans available to settle obligations of a consolidated VIE as of December 31, 2024 and 2023, respectively. | text | 28.6 | monetaryItemType | text: <entity> 28.6 </entity> <entity type> monetaryItemType </entity type> <context> Includes approximately $ 28.3 billion and $ 28.6 billion of gross Card Member loans available to settle obligations of a consolidated VIE as of December 31, 2024 and 2023, respectively. </context> | us-gaap:NotesReceivableGross |
Other loans are presented net of reserves for credit losses of $ 194 million and $ 126 million as of December 31, 2024 and 2023, respectively. | text | 194 | monetaryItemType | text: <entity> 194 </entity> <entity type> monetaryItemType </entity type> <context> Other loans are presented net of reserves for credit losses of $ 194 million and $ 126 million as of December 31, 2024 and 2023, respectively. </context> | us-gaap:FinancingReceivableAllowanceForCreditLosses |
Other loans are presented net of reserves for credit losses of $ 194 million and $ 126 million as of December 31, 2024 and 2023, respectively. | text | 126 | monetaryItemType | text: <entity> 126 </entity> <entity type> monetaryItemType </entity type> <context> Other loans are presented net of reserves for credit losses of $ 194 million and $ 126 million as of December 31, 2024 and 2023, respectively. </context> | us-gaap:FinancingReceivableAllowanceForCreditLosses |
Includes $ 3.9 billion and $ 4.6 billion of gross Card Member receivables available to settle obligations of a consolidated VIE as of December 31, 2024 and 2023, respectively. | text | 3.9 | monetaryItemType | text: <entity> 3.9 </entity> <entity type> monetaryItemType </entity type> <context> Includes $ 3.9 billion and $ 4.6 billion of gross Card Member receivables available to settle obligations of a consolidated VIE as of December 31, 2024 and 2023, respectively. </context> | us-gaap:NotesReceivableGross |
Includes $ 3.9 billion and $ 4.6 billion of gross Card Member receivables available to settle obligations of a consolidated VIE as of December 31, 2024 and 2023, respectively. | text | 4.6 | monetaryItemType | text: <entity> 4.6 </entity> <entity type> monetaryItemType </entity type> <context> Includes $ 3.9 billion and $ 4.6 billion of gross Card Member receivables available to settle obligations of a consolidated VIE as of December 31, 2024 and 2023, respectively. </context> | us-gaap:NotesReceivableGross |
Such modifications to the loans and receivables primarily include (i) temporary interest rate reductions (reducing interest rates to as low as zero percent, in which case the loan is characterized as non-accrual) and/or (ii) placing the customer on a fixed payment plan not to exceed 60 months. Upon entering the modification program, the customer’s ability to make future purchases is limited, canceled or, in certain cases, suspended until the customer successfully exits from the modification program. As of December 31, 2024, we had $ 82 million of unused credit available to customers with loans and receivables modified during the year ended December 31, 2024. In accordance with the modification agreement with the customer, loans and/or receivables may revert to the original contractual terms (including the contractual interest rate where applicable) when the customer exits the modification program, which is either (i) when all payments have been made in accordance with the modification agreement or (ii) when the customer defaults out of the modification program. | text | 82 | monetaryItemType | text: <entity> 82 </entity> <entity type> monetaryItemType </entity type> <context> Such modifications to the loans and receivables primarily include (i) temporary interest rate reductions (reducing interest rates to as low as zero percent, in which case the loan is characterized as non-accrual) and/or (ii) placing the customer on a fixed payment plan not to exceed 60 months. Upon entering the modification program, the customer’s ability to make future purchases is limited, canceled or, in certain cases, suspended until the customer successfully exits from the modification program. As of December 31, 2024, we had $ 82 million of unused credit available to customers with loans and receivables modified during the year ended December 31, 2024. In accordance with the modification agreement with the customer, loans and/or receivables may revert to the original contractual terms (including the contractual interest rate where applicable) when the customer exits the modification program, which is either (i) when all payments have been made in accordance with the modification agreement or (ii) when the customer defaults out of the modification program. </context> | us-gaap:LoansAndLeasesReceivableImpairedCommitmentToLend |
Provisions for principal, interest and fee reserve components. Provisions for credit losses includes reserve build (release) and replenishment for net write-offs. In addition, provisions for the year ended December 31, 2024 includes the reserve release of $ 49 million upon the reclassification of Card Member loans related to the Lowe’s small business cobrand portfolio as HFS in the fourth quarter of 2024. See Note 1 for additional information. | text | 49 | monetaryItemType | text: <entity> 49 </entity> <entity type> monetaryItemType </entity type> <context> Provisions for principal, interest and fee reserve components. Provisions for credit losses includes reserve build (release) and replenishment for net write-offs. In addition, provisions for the year ended December 31, 2024 includes the reserve release of $ 49 million upon the reclassification of Card Member loans related to the Lowe’s small business cobrand portfolio as HFS in the fourth quarter of 2024. See Note 1 for additional information. </context> | us-gaap:ProvisionForLoanLossesExpensed |
Principal write-offs are presented less recoveries of $ 730 million, $ 537 million and $ 539 million for the years ended December 31, 2024, 2023 and 2022, respectively. Recoveries of interest and fees were not significant. | text | 730 | monetaryItemType | text: <entity> 730 </entity> <entity type> monetaryItemType </entity type> <context> Principal write-offs are presented less recoveries of $ 730 million, $ 537 million and $ 539 million for the years ended December 31, 2024, 2023 and 2022, respectively. Recoveries of interest and fees were not significant. </context> | us-gaap:FinancingReceivableAllowanceForCreditLossesRecovery |
Principal write-offs are presented less recoveries of $ 730 million, $ 537 million and $ 539 million for the years ended December 31, 2024, 2023 and 2022, respectively. Recoveries of interest and fees were not significant. | text | 537 | monetaryItemType | text: <entity> 537 </entity> <entity type> monetaryItemType </entity type> <context> Principal write-offs are presented less recoveries of $ 730 million, $ 537 million and $ 539 million for the years ended December 31, 2024, 2023 and 2022, respectively. Recoveries of interest and fees were not significant. </context> | us-gaap:FinancingReceivableAllowanceForCreditLossesRecovery |
Principal write-offs are presented less recoveries of $ 730 million, $ 537 million and $ 539 million for the years ended December 31, 2024, 2023 and 2022, respectively. Recoveries of interest and fees were not significant. | text | 539 | monetaryItemType | text: <entity> 539 </entity> <entity type> monetaryItemType </entity type> <context> Principal write-offs are presented less recoveries of $ 730 million, $ 537 million and $ 539 million for the years ended December 31, 2024, 2023 and 2022, respectively. Recoveries of interest and fees were not significant. </context> | us-gaap:FinancingReceivableAllowanceForCreditLossesRecovery |
Primarily includes foreign currency translation adjustments of $( 33 ) million, $ 18 million and $( 6 ) million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 33 | monetaryItemType | text: <entity> 33 </entity> <entity type> monetaryItemType </entity type> <context> Primarily includes foreign currency translation adjustments of $( 33 ) million, $ 18 million and $( 6 ) million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation |
Primarily includes foreign currency translation adjustments of $( 33 ) million, $ 18 million and $( 6 ) million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 18 | monetaryItemType | text: <entity> 18 </entity> <entity type> monetaryItemType </entity type> <context> Primarily includes foreign currency translation adjustments of $( 33 ) million, $ 18 million and $( 6 ) million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation |
Primarily includes foreign currency translation adjustments of $( 33 ) million, $ 18 million and $( 6 ) million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 6 | monetaryItemType | text: <entity> 6 </entity> <entity type> monetaryItemType </entity type> <context> Primarily includes foreign currency translation adjustments of $( 33 ) million, $ 18 million and $( 6 ) million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation |
Net write-offs are presented less recoveries of $ 304 million, $ 297 million and $ 257 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 304 | monetaryItemType | text: <entity> 304 </entity> <entity type> monetaryItemType </entity type> <context> Net write-offs are presented less recoveries of $ 304 million, $ 297 million and $ 257 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:FinancingReceivableAllowanceForCreditLossesRecovery |
Net write-offs are presented less recoveries of $ 304 million, $ 297 million and $ 257 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 297 | monetaryItemType | text: <entity> 297 </entity> <entity type> monetaryItemType </entity type> <context> Net write-offs are presented less recoveries of $ 304 million, $ 297 million and $ 257 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:FinancingReceivableAllowanceForCreditLossesRecovery |
Net write-offs are presented less recoveries of $ 304 million, $ 297 million and $ 257 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 257 | monetaryItemType | text: <entity> 257 </entity> <entity type> monetaryItemType </entity type> <context> Net write-offs are presented less recoveries of $ 304 million, $ 297 million and $ 257 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:FinancingReceivableAllowanceForCreditLossesRecovery |
Primarily includes foreign currency translation adjustments of $( 4 ) million, $ 1 million and $ 2 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 4 | monetaryItemType | text: <entity> 4 </entity> <entity type> monetaryItemType </entity type> <context> Primarily includes foreign currency translation adjustments of $( 4 ) million, $ 1 million and $ 2 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation |
Primarily includes foreign currency translation adjustments of $( 4 ) million, $ 1 million and $ 2 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 1 | monetaryItemType | text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> Primarily includes foreign currency translation adjustments of $( 4 ) million, $ 1 million and $ 2 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation |
Primarily includes foreign currency translation adjustments of $( 4 ) million, $ 1 million and $ 2 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 2 | monetaryItemType | text: <entity> 2 </entity> <entity type> monetaryItemType </entity type> <context> Primarily includes foreign currency translation adjustments of $( 4 ) million, $ 1 million and $ 2 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:FinancingReceivableAllowanceForCreditLossForeignCurrencyTranslation |
Investment securities principally include available-for-sale (AFS) debt securities carried at fair value on the Consolidated Balance Sheets. The methodology for estimating credit losses for AFS debt securities requires us to estimate lifetime credit losses for all AFS debt securities in an unrealized loss position. When estimating a security’s probability of default and the recovery rate, we assess the security’s credit indicators, including credit ratings. If our assessment indicates that an estimated credit loss exists, we determine the portion of the unrealized loss attributable to credit deterioration and record a reserve for the estimated credit loss through the Consolidated Statements of Income in Other loans Provision for credit losses. Unrealized gains and any portion of a security’s unrealized loss attributable to non-credit losses are recorded in the Consolidated Statements of Comprehensive Income, net of tax. We had accrued interest on our AFS debt securities totaling $ 3 million and $ 5 million as of December 31, 2024 and 2023, respectively, presented as Other assets on the Consolidated Balance Sheets. | text | 3 | monetaryItemType | text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> Investment securities principally include available-for-sale (AFS) debt securities carried at fair value on the Consolidated Balance Sheets. The methodology for estimating credit losses for AFS debt securities requires us to estimate lifetime credit losses for all AFS debt securities in an unrealized loss position. When estimating a security’s probability of default and the recovery rate, we assess the security’s credit indicators, including credit ratings. If our assessment indicates that an estimated credit loss exists, we determine the portion of the unrealized loss attributable to credit deterioration and record a reserve for the estimated credit loss through the Consolidated Statements of Income in Other loans Provision for credit losses. Unrealized gains and any portion of a security’s unrealized loss attributable to non-credit losses are recorded in the Consolidated Statements of Comprehensive Income, net of tax. We had accrued interest on our AFS debt securities totaling $ 3 million and $ 5 million as of December 31, 2024 and 2023, respectively, presented as Other assets on the Consolidated Balance Sheets. </context> | us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.